The Partnerships: A Global Team of Science
​Australian Government
and University
The University of Adelaide and the South Australian Health and Medical Research Institute are pursuing the PREACH-M Phase 2/3 study for life-threatening Chronic Myelomonocytic Leukemia (CMML), an orphan condition. Early results showed the LENZ response rate of 78% compared to around 20% for the standard of care. Results were reported in posters presented at the American Society offer Hematology in December 2023.
Mayo Clinic
The Mayo Clinic is planning to study LENZ to potentially increase the safety and effectiveness of CAR-T cancer therapy, supported by positive Phase 1b results. Taran will contribute a small portion of the total study cost, expected to involve 160 patients over four years, with the majority of funding contributed by Mayo and commercial payers.
​UK’s Impact Partnership
Government funded researchers in the UK are pursuing the RATinG Phase 2/3 study in the early treatment of Acute Graft-Versus-Host Disease (aGvHD). This is a randomized, double-blind, placebo-controlled study investigating LENZ among the 50%-70% of Hematopoietic Cell Transplantation (HCT) patients who develop aGvHD. With current treatment, only 25%-30% of patients with grade III disease survive more than two years. This study has recently begun enrolling.